Name:
Institution:
Type:
PI
Therapeutic Candidate or Device
Tumor stem cell-targeted immunotherapy.
Indication
Metastatic melanoma.
Therapeutic Mechanism
Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival.
Unmet Medical Need
There is no effective treatment for metastatic melanoma. This treatment is the only one to target tumor stem cells in melanoma patients.
Project Objective
Complete Phase 3 trial to support BLA approval.
Major Proposed Activities